Lv Lulu, Huang Ruo Han, Li Jiale, Xu Jing, Gao Wen
Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing, 210029, China.
Biomark Res. 2022 Aug 29;10(1):66. doi: 10.1186/s40364-022-00412-1.
It is known that metabolic reprogramming (MR) contributes to tumorigenesis through the activation of processes that support survival of cells, proliferation, and grow in the tumor microenvironment. In order to keep the tumor proliferating at a high rate, metabolic pathways must be upregulated, and tumor metabolism must be adapted to meet this requirement. Additionally, immune cells engage in metabolic remodeling to maintain body and self-health. With the advent of immunotherapy, the fate of individuals suffering from non-small cell lung cancer (NSCLC) has been transformed dramatically. MR may have a profound influence on their prognosis. The aim of this review is to summarize current research advancements in metabolic reprogramming and their impact on immunotherapy in NSCLC. Moreover, we talk about promising approaches targeting and manipulating metabolic pathways to improve cancer immunotherapy's effectiveness in NSCLC.
众所周知,代谢重编程(MR)通过激活支持细胞存活、增殖以及在肿瘤微环境中生长的过程来促进肿瘤发生。为了使肿瘤以高速度增殖,代谢途径必须上调,并且肿瘤代谢必须进行调整以满足这一需求。此外,免疫细胞会进行代谢重塑以维持机体和自身健康。随着免疫疗法的出现,非小细胞肺癌(NSCLC)患者的命运发生了巨大转变。代谢重编程可能对其预后产生深远影响。本综述的目的是总结代谢重编程的当前研究进展及其对NSCLC免疫疗法的影响。此外,我们还讨论了针对和操纵代谢途径以提高癌症免疫疗法在NSCLC中的有效性的有前景的方法。